Bringing more than 20 years of experience as a senior level executive in the global pharmaceutical and biotech industry, Francois Martelet will join Scandion Oncology on January 2, 2023.
Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announces that the company’s Board of Directors has appointed Francois Martelet as new Chief Executive Officer (CEO). Francois will take up his new position on January 2, 2023.
Trained as a Medical Doctor with a Master’s degree in Business, Francois Martelet is an experienced executive and CEO with a career spanning more than 30 years in the global pharmaceutical and biotech industry and more than 20 years of experience as an executive. He has significant experience within early and late-stage clinical development in oncology (cancer) as well as business and partnership development.
“We are delighted to appoint Francois Martelet as the new CEO of Scandion. Francois brings a wealth of highly relevant experiences to Scandion as an experienced and passionate business leader with the qualifications to successfully develop Scandion and our lead asset, SCO-101”, says Martin Møller, Chairman of the Board of Directors of Scandion.
Francois Martelet has worked and held leadership positions in large pharmaceutical companies including Roche, Eli Lilly, Novartis and MSD. He has also been the CEO of a number of biotech companies, most recently Vivesto AB, where he completed a full turnaround and led the build-up of an oncology pipeline through organic and external growth.
“I am very excited by the opportunity to join and lead Scandion in its pursuit to revert cancer drug resistance, which would make a tremendous difference to patients. Scandion has a huge medical and therefore commercial potential which I am looking forward to help fulfil”, says Francois Martelet.
Acting CEO & CFO Johnny Stilou will continue in this role until January 2, 2023, and afterwards resume his role as CFO of Scandion.
For further information please contact:
Martin Møller, Chairman of the Board
Phone: +45 2960 3532
E-mail: ir@scandiononcology.com
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on December 1, 2022, at 08.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market.